VIKING GLOBAL INVESTORS LP 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-12 4:28 pm Unchanged |
2025-01-31 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% |
0 (Unchanged) |
Filing |
| 2025-01-31 7:18 pm Sale |
2025-01-31 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% |
-3,065,616 (-12.20%) |
Filing |
| 2024-11-06 5:04 pm Unchanged |
2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% |
0 (Unchanged) |
Filing |
| 2024-08-20 8:42 pm Unchanged |
2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% |
0 (Unchanged) |
Filing |
| 2023-11-22 4:15 pm Unchanged |
2023-07-18 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 15.700% |
0 (Unchanged) |
Filing |
| 2023-07-19 9:52 pm Sale |
2023-07-18 | 13D | BridgeBio Pharma, Inc. BBIO |
VIKING GLOBAL INVESTORS LP | 25,120,991 15.700% |
-1,500,000 (-5.63%) |
Filing |